Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion

Retrovirology

Volumn 3, Issue , 2006, Pages

  Gallo, Stephen A ^a   Reeves, Jacqueline D ^b   Garg, Himanshu ^a   Foley, Brian T ^c   Doms, Robert W ^b   Blumenthal, Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; VIRUS ENVELOPE PROTEIN;

ARTICLE; BINDING AFFINITY; BINDING SITE; CELL FUSION; COMPARATIVE STUDY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG MECHANISM; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; LYMPHOMA CELL LINE; MEMBRANE FUSION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN CONFORMATION; RECEPTOR BINDING; STRAIN DIFFERENCE; VIRUS CELL INTERACTION; VIRUS STRAIN;

ANTIGENS, CD4; CELL LINE; HELA CELLS; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV-1; HIV-2; HUMANS; KINETICS; MEMBRANE FUSION; RECEPTORS, CXCR4;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 33845892134     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-3-90     Document Type: Article

References (43)

1. Hahn BH, Shaw GM, De Cock KM, Sharp PM: AIDS as a zoonosis: scientific and public health implications. Science 2000, 287:607-614.
2. Reeves JD, Doms RW: Human immunodeficiency virus type 2. J Gen Virol 2002, 83:1253-1265.
3. Gallo SA, Sackett K, Rawat SS. Shai Y, Blumenthal R: The Stability of the Intact Envelope Glycoproteins is a Major Determinant of Sensitivity of HIV/SIV to Peptidic Fusion Inhibitors. J Mol Biol 2004, 340:9-14.
4. Blumenthal R, Clague MJ, Durell SR, Epand RM: Membrane fusion. Chem Rev 2003, 103:53-69.
5. Gustchina E, Hummer G, Bewley CA, Clore GM: Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV. J Med Chem 2005, 48:3036-3044.
6. Jernigan KM, Blumenthal R, Puri A: Varying effects of temperature, Ca(2+) and cytochalasin on fusion activity mediated by human immunodeficiency virus type 1 and type 2 glycoproteins. FEBS Lett 2000, 474:246-251.
7. Puri A, Hug P, Munoz-Barroso I, Blumenthal R: Human erythrocyte glycolipids promote HIV-1 envelope glycoprotein-mediated fusion of CD4+ cells. Biochem Biophys Res Commun 1998, 242:219-225.
8. Gallo SA, Finnegan CM, Viard M. Raviv Y, Dimitrov A, Rawat SS, Puri A, Durell S, Blumenthal R: The HIV Env-mediated fusion reaction. Biochim Biophys Acta 2003, 1614:36-50.
9. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, Pohlmann S, Sfakianos JN, Derdeyn CA, Blumenthal R, Hunter E, Doms RW: Sensitivity of HIV-1 to entry inhibitors correlates with envelope/ coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A 2002, 99:16249-16254.
10. Reeves JD, Miamidian JL, Biscone MJ, Lee FH, Ahmad N, Pierson TC, Doms RW: Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J Virol 2004, 78:5476-5485.
11. Gallo SA, Puri A, Blumenthal R: HIV-1 gp41 Six-Helix Bundle Formation Occurs Rapidly after the Engagement of gp120 by CXCR4 in the HIV-1 Env-Mediated Fusion Process. Biochemistry 2001, 40:12231-12236.
12. Chan DC, Kim PS: HIV entry and its inhibition. Cell 1998, 93:681-684.
13. Furuta RA, Wild CT, Weng Y, Weiss CD: Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 1998, 5:276-279.
14. Weissenhorn W, Dessen A, Calder LJ, Harrison SC, Skehel JJ, Wiley DC: Structural basis for membrane fusion by enveloped viruses. Mol Membr Biol 1999, 16:3-9.
15. Doms RW, Moore JP: HIV-1 membrane fusion: targets of opportunity. J Cell Biol 2000, 151:F9-14.
16. Sodroski JG: HIV-1 entry inhibitors in the side pocket. Cell 1999, 99:243-246.
17. Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, Cohen FS: Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 2000, 151:413-423.
18. Munoz-Barroso I, Durell S, Sakaguchi K, Appella E, Blumenthal R: Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol 1998, 140:315-323.
19. Salzwedel K, Berger EA: Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: Functional complementation of specific defects in gp120 and gp41. Proceedings of the National Academy of Sciences 2000, 97:12794-12799.
20. Wyss S, Dimitrov AS, Baribaud F, Edwards TG, Blumenthal R, Hoxie JA: Regulation of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Fusion by a Membrane-Interactive Domain in the gp41 Cytoplasmic Tail. J Virol 2005, 79:12231-12241.
21. Kim JT, Kim EM, Lee KH, Choi JE, Jhun BH, Kim JW: Leucine zipper domain of HIV-1 gp41 interacted specifically with alpha-catenin. Biochem Biophys Res Commun 2002, 291:1239-1244.
22. Tencza SB, Miller MA, Islam K, Mietzner TA, Montelaro RC: Effect of amino acid substitutions on calmodulin binding and cytolytic properties of the LLP-1 peptide segment of human immunodeficiency virus type 1 transmembrane protein. J Virol 1995, 69:5199-5202.
23. Zhang H, Wang L, Kao S, Whitehead IP, Hart MJ, Liu B, Duus K. Burridge K, Der CJ, Su L: Functional interaction between the cytoplasmic leucine-zipper domain of HIV-1 gp41 and p115-RhoGEF. Curr Biol 1999, 9:1271-1274.
24. Evans DT, Tillman KC, Desrosiers RC: Envelope glycoprotein cytoplasmic domains from diverse lentiviruses interact with the prenylated Rab acceptor. J Virol 2002, 76:327-337.
25. Wyss S, Berlioz-Torrent C, Boge M, Blot G, Honing S, Benarous R, Thali M: The highly conserved C-terminal dileucine motif in the cytosolic domain of the human immunodeficiency virus type I envelope glycoprotein is critical for its association with the AP-1 clathrin adaptor [correction of adapter]. J Virol 2001, 75:2982-2992.
26. Miller MA. Cloyd MW, Liebmann J, Rinaldo CR Jr, Islam KR, Wang SZ, Mietzner TA, Montelaro RC: Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein. Virology 1993, 196:89-100.
27. Kliger Y, Shal Y: A leucine zipper-like sequence from the cytoplasmic tail of the HIV-1 envelope glycoprotein binds and perturbs lipid bilayers. Biochemistry 1997, 36:5157-5169.
28. Comardelle AM, Norris CH, Plymale DR, Gatti PJ, Choi B, Fermin CD, Haislip AM, Tencza SB, Mietzner TA, Montelaro RC, Garry RF: A synthetic peptide corresponding to the carboxy terminus of human immunodeficiency virus type 1 transmembrane glycoprotein induces alterations in the ionic permeability of Xenopus laevis oocytes. AIDS Res Hum Retroviruses 1997, %20;13:1525-1532.
29. Freed EO, Martin MA: Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol 1996, 70-341-351.
30. Wyma DJ, Kotov A, Aiken C: Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles. J Virol 2000, 74:9301-9387.
31. Wyma DJ, Jiang J, Shi J, Zhou J, Lineberger JE, Miller MD, Aiken C: Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail. J Virol 2004, 78:3429-3435.
32. Murakami T, Ablan S, Freed EO, Tanaka Y: Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity. J Virol 2004, 78:1026-1031.
33. Abrahamyan LG, Mkrtchyan SP, Binley J, Lu M, Melikyan GB, Cohen FS: The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle. J Virol 2005, 79:106-115.
34. Edwards TG, Wyss S, Reeves JD, Zolla-Pazner S, Hoxie JA, Doms RW, Baribaud F: Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J Virol 2002, 76:2683-2691.
35. Schols D, Struyf S, Van Damme J, Este JA, Henson G. De Clercq E: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997, 186:1383-1388.
36. Sattentau QJ, Dalgleish AG, Weiss RA, Beverley PC: Epitopes of the CD4 antigen and HIV infection. Science 1986, 234:1120-1123.
37. Hoffman TL, LaBranche CC, Zhang W, Canziani G, Robinson J, Chaiken I, Hoxie JA, Doms RW: Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc Natl Acad Sci U S A 1999, 96:6359-6364.
38. Lin G, Baribaud F, Romano J, Doms RW, Hoxie JA: Identification of gp120 binding sites an CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins. J Virol 2003, 77:931-942.
39. Earl PL, Koenig S, Moss B: Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. J Virol 1991, 65:31-41.
40. Mulligan MJ, Ritter GD Jr, Chaikin MA, Yamshchikov GV, Kumar P, Hahn BH, Sweet RW, Compans RW: Human immunodeficiency virus type 2 envelope glycoprotein: differential CD4 interactions of soluble gp120 versus the assembled envelope complex. Virology 1992, 187:233-241.
41. Chakrabarti S, Mizukami T, Franchini G, Moss B: Synthesis, oligomerization, and biological activity of the human immunodeficiency virus type 2 envelope glycoprotein expressed by a recombinant vaccinia virus. Virology 1990, 178:134-142.
42. Reeves JD, Schulz TF: The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion. J Virol 1997, 71:1453-1465.
43. Edinger AL, Blanpain C, Kunstman KJ, Wolinsky SM, Parmentier M, Doms RW: Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains. J Virol 1999, 73:4062-4073.